In the routine practice, ER−/PgR + subtype breast cancer was considered as endocrine-related and would receive endocrine therapy and chemotherapy of which the protocol was with moderate strength given the estimated favorable prognosis. This evidence concerns the gene ESR1 and breast cancer.